Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences

November 9, 2009 9:31 AM EST

CALGARY, Alberta, Nov. 9, 2009 (GLOBE NEWSWIRE) -- Emerging Stock Report, a leading provider of sector specific independent investment research, today initiated coverage on Human Genome Sciences (HGSI). Emerging Stock Report is currently offering a complimentary trial subscription to the investment community.

The investment report on Human Genome Sciences (Nasdaq: HGSI) should be of particular interest to biopharmaceutical Industry comparables: Novartis AG (NYSE: NVS), AstraZeneca plc (NYSE: AZN), Bristol-Myers Squibb Co. (NYSE: BMY) and Talecris Biotherapeutics Holding Corp. (Nasdaq: TLCR).

To view the Report in its entirety visit: http://www.emergingstockreport.com

To get our alerts AHEAD of the market follow us on Twitter: http://twitter.com/EmergingStockRe

About ESR:

Emerging Stock Report is a leading provider of independent investment research for North American companies. Our services include research analysis on emerging growth companies, sector specific research, real-time news and financial data, market commentary and the ESR newsletter. Emerging Stock Report's staff of investment professionals are dedicated to providing the the tools and resources necessary to help make important investment decisions. To view our research reports on a complimentary trial basis and take advantage of our other services, visit http://www.emergingstockreport.com and click on the complimentary trial subscription button on our home page, or go directly to our registration page at http://emergingstockreport.com/register.php

About Human Genome Sciences :

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat lupus, hepatitis C, inhalation anthrax and cancer.

The Company's primary focus is rapid progress toward the commercialization of its two lead drugs, BENLYSTA(tm) (belimumab) for lupus and ZALBIN(tm) (albinterferon alfa-2b) for hepatitis C. BENLYSTA has successfully met its primary endpoint in two pivotal Phase 3 trials in systemic lupus erythematosus, and the submission of marketing applications in the U.S., Europe and other regions is planned in the first half of 2010. ZALBIN has completed Phase 3 development, and the submission of global marketing applications is planned in fourth quarter 2009. In May 2009, HGS submitted a Biologics License Application to the FDA for raxibacumab for the treatment of inhalation anthrax. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, currently in Phase 3 development in patients with coronary heart disease, and Syncria(r) (albiglutide), currently in Phase 3 development in patients with type 2 diabetes.

For more information about HGS, please visit the Company's web site at www.hgsi.com.

ESR Disclosure:

Emerging Stock Report is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. Emerging Stock Report has not been compensated by any of the above mentioned companies. Please read our report and visit our Web site, http://www.EmergingStockReport.com, for complete risks and disclosures.

CONTACT:  Emerging Stock Report
          Dylan Anderson
          1 (206) 905 9680
          info@emergingstockreport.com

Related Categories

Press Releases

Stocks Mentioned

Related Entities

• Twitter

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?